惰性淋巴瘤规范化治疗－八年NCCN治疗指南解读文件材料.pptVIP

惰性淋巴瘤规范化治疗 －08年NCCN治疗指南解读 ; Hungary ,Budapest 2008;Years;Years;Years ;惰性淋巴瘤治疗效果提高; Rituximab:惰性 NHL(FL);一线 - 滤泡性淋巴瘤治疗: Randomized;Rituximab 维持治疗的进展;;Radio-Immuno-Therapy 单用;CD20 -I 131:FL and Transformed NHL:Long term outcome;  方 案;CUP trial: AHSCT欧洲多中心研究; CUP trial: progression-free survival ;AutoPBSCT in 1st Remission FL;AHSCT 1st-line :follicular lymphoma; Rituximab and/or High-Dose Therapy with Autotransplant at Time of Relapse in FL ;Improved supportive therapy and outcome after Auto vs. Allo transplantation?;;;;;;How I treat indolent lymphoma;Years; ;; Fludarabine ( 单药 );福达华 + 米托蒽琨;初治;比较FCN +/- CD20单抗的疗效 49例患者进行初步疗效评价 两组的血液学和非血液学毒性相当; FLU vs FLU-ID (FLU+Ida) (Bologna) FND vs ATT (MDACC) FC vs CVP ? Anti-20 (ECOG) FND followed by anti-CD20 vs FND plus anti-CD20 concurrenty (MDACC) FM vs CHOP ? anti-CD20 (Bologna);FLU;8个疗程的FND方案与ATT(CHOD-Bleo, ESHAP, NOPP)治疗IV期惰性淋巴瘤的随机对照研究 报道的5年OS内分子学CR情况两组没有差异(bcl-2-): 84 % FND vs 82 % ATT; 5-year FFS: 41 % FND vs 50 % ATT;RANDOMIZED PHASE III TRIAL;FM对比CHOP（±CD20）初治滤泡性淋巴瘤随机对照研究;FM对比CHOP：完全缓解率和分子学完全缓解率显著提高;FM对比CHOP：RFS;FM对比CHOP：耐受性显著提高;含福达华方案;1.含Fludarabine 联合方案治 疗 复 发 恶 性 NHL; Objective Response;2.含Fludarabine方案治疗初治/复治惰性淋巴瘤;疗 效; 滤泡性淋巴瘤治疗Meta分析;10 mg 迅速释放的片剂 药代动力学研究Foran et al., J Clin Oncol 199940-50 mg/m2 口服相当于25 mg/m2 i.v. 生物利用度不受食物影响Oscier et al., Hematol J 2001;口服 vs 静脉 : 疗效相当（单药CLL）;Oral Fludarabine + CTX :75 untreated CLL:Final response and F/U ;Oral fludarabine +CTX : 75 untreated CLLFinal response and F/U ;口服 Fludarabine + CTX治疗惰性淋巴瘤 初步结果报告;Oral Fludarabine + CTX; Response Rate;LQY , 59岁. CLL/SLL 17年;问 题;NEW ADVANCES;FLUDARABINE ＋MIT + Zevalin 87 UNTREATED INDOLENT NHL;LUMILIXIMAB (anti-CD23) - FCR : RELAPSED CLL;12 例,男8 女4, relapsed, refractory FL A ( V+R ) B ( R) N 5